The current ratio's decline from 6.07 to 1.38 over ten quarters reflects a severe erosion of liquid assets relative to current liabilities, driven by sustained cash burn with no revenue. With cash and equivalents at $71.9 million and quarterly net losses averaging around $60 million, the company appears to have less than two quarters of funding, suggesting imminent liquidity stress. This thin buffer leaves little room for operational shocks or clinical trial delays, and investors should monitor whether management can secure additional financing before the cushion is exhausted.

The D/E ratio's increase from 0.28 to 0.48 is not due to new borrowing but rather a 59% decline in shareholders' equity from $375.1 million to $154.6 million, while debt only fell from $106.1 million to $73.7 million. This indicates that leverage is becoming a larger burden relative to the shrinking capital base, and with no interest coverage data available, the comfort of debt service is unclear. The rising leverage, combined with a thin equity cushion, suggests that any further losses could push the balance sheet toward negative equity, especially if goodwill impairment materializes.

The ROIC trend shows a clear deterioration, with the metric worsening from -12.2% to -34.8% over the last ten quarters, despite a temporary improvement in early 2025. This decline is driven by sustained operating losses against a shrinking invested capital base, as the company burns through cash without generating returns. The ROE decline from -14.1% to -46.5% is even steeper, reflecting the rapid erosion of equity, and suggests that the company is not compounding but rather decaying its capital base, with no near-term prospect of positive returns.

With no revenue, traditional efficiency ratios like asset turnover and cash conversion cycle are not meaningful, as the company's operations are purely cost-focused. The only observable efficiency signal is the current ratio, which has fallen from 6.07 to 1.38, suggesting that current liabilities are growing relative to current assets, possibly due to increased payables or accrued expenses. This trend implies that Sana is becoming less efficient at managing its limited working capital, though the lack of detailed data warrants caution in drawing firm conclusions.

Sana's P/B of 5.79 is significantly higher than FATE's 1.50, CRSP's 2.54, and BEAM's 2.16, indicating that investors are paying a premium for its book value, likely due to the perceived value of its hypoimmune platform. However, this premium is not supported by superior returns, as Sana's ROE of -46.5% is worse than CRSP's -24.4% and BEAM's -7.7%, though better than EDIT's -196.6%. The gap in P/B may reflect market optimism about the in vivo fusogen platform, but the low cash position relative to peers suggests a higher risk of dilution, which could compress the multiple.